The November 2019 issue of Pharmafocus is available to read for free online now!
pharmafile | October 30, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |
Brexit has been predictably dangled overhead and yanked out of reach yet again here in the UK, replaced by a December general election that feels a bit like the Christmas present nobody asked for. The NHS and healthcare in the UK is likely to be a key topic of debate over the coming weeks. On the front line of the Labour Party’s policy ranks is its plan to nationalise, in part, the industry that supplies the country’s medicines and curb the pursuit of profit by pharmaceutical firms.
This has not gone down well with the ABPI, the UK’s representative body for the pharma industry, and it did not hold back in its defence; you can read the response on page 5.
In other news, J&J is starting to feel the toll of its ongoing legal battles to defend its opioid and talc products, as a new Alva report reveals that the company has fallen to 57th of 58 on a reputation ranking of pharma firms. You can read the story of this fall from grace, with exclusive comment from Alva’s Alastair Pickering, on page 8.
We also round up the biggest developments in cancer R&D at the European Society for Medical Oncology (ESMO) 2019, including breaking announcements from AstraZeneca, MSD, BMS and more in our event review, located on page 17.
We also have full-length features focusing on the rise of biosimilar medicines and how virtual tools and strategies may help overcome the shortcomings of the traditional clinic trial. Read all that and more in the full edition, available online here.
